Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst

seekingalpha04-07

Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2425944612?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/652879820/image_652879820.jpg","is_english":true,"pubTime":"2024-04-07 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2425944612","market":"hk","top_or_hot":-1,"title":"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst","media":"seekingalpha","content":"<div>\n<p>Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst.  The ...</p>\n\n<a href=\"https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-07 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst.  The ...</p>\n\n<a href=\"https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst","article_id":"2425944612","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/652879820/image_652879820.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2425944612","pubTimestamp":1712491200,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst.  The thr","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","SQQQ":"纳指三倍做空ETF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4534":"瑞士信贷持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BIIB":"渤健公司","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","PFE":"辉瑞","PSQ":"纳指反向ETF","BK4559":"巴菲特持仓","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","QLD":"纳指两倍做多ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC",".IXIC":"NASDAQ Composite","QQQ":"纳指100ETF","BAYRY":"Bayer A.G.","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","REGN":"再生元制药公司","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","03165":"华夏欧优股对冲","RYTM":"Rhythm Pharmaceuticals Inc.","PHAT":"Phathom Pharmaceuticals","TAK":"武田制药","PFE.AU":"PANTERA MINERALS LTD","BMY":"施贵宝","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","TQQQ":"纳指三倍做多ETF","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","RHHBY":"罗氏控股","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","QID":"纳指两倍做空ETF","PCVX":"Vaxcyte, Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Phathom Pharma、Rhythm、Vaxcyte最有可能成为制药行业的收购目标——分析师","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1,"BAYRY":1,"BIIB":1,"TAK":1,"PFE.AU":1,"PFE":1,"BMY":1,"PCVX":1,"RYTM":1,"RHHBY":1,"REGN":1,".IXIC":0.76,"QQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"03165":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst.  The three companies are the most likely to be acquired in Needham's coverage universe, Needham analyst Joseph Stringer wrote in a note on Friday. Needham has a buy rating and $26 price target on Phathom (PHAT), a buy rating and $95 price target on Vaxcyte (PCVX) and a $50 price target and buy rating on Rhythm (RYTM). \"We think M&A activity will remain above average for the remainder of 2024 and skew more toward mid-stage target companies, with deal sizes in the $1-3B range and a particular focus on Oncology, Immunology, and Rare Disease,\" Stringer wrote in the note. Stringer highlighted that there were a total of 13 M&A deals during Q1, which was well above the 8.2 quarterly average since 2018, and the 7 deals for public companies were above the 4.9 quarterly average since 2018. Stringer expects that Bayer (OTCPK:BAYRY), Roche (OTCQX:RHHBY), and Regeneron (REGN) are most likely to buy earlier-stage companies. Takeda Pharmaceutical (TAK), Biogen (BIIB), Bristol-Myers Squibb (BMY), and Pfizer (PFE) are most likely to buy late-stage companies. \"Average deal size, 1-day premiums, and equity takeout multiples have all hovered around their respective historical averages over the last several quarters,\" Stringer explained. \"A preference for later-stage companies is still evident, but we note a recent flurry of deals for earlier-stage biotech companies may reflect Pharma's increased appetite for more risk-on assets.\"  The Needham analyst also highlighted that average takeout premiums appear to be declining. In 1Q24, the average 1-day takeout premium was 73%, below the historical avg. of 77%. Equity takeout multiples have also trended down over the last several quarters, according to Stringer. Of the 4 most recent public deals for which financial data are available, all were below the historical average.  More on Phathom Pharmaceuticals  Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals Historical earnings data for Phathom Pharmaceuticals Financial information for Phathom Pharmaceuticals","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425944612"}